title: Bone remodeling after administration of proton pump (H+/K+-ATPase) inhibitors and alendronate in ovariectomized rats.
abstract: During osteoporosis therapy with alendronate, esophagitis and stomach ulceration may occur, requiring the concurrent use of drugs which decrease gastric juice production. The aim of the present study was to investigate the effect of concurrent administration of proton pump (H+/K+ATP-ase) inhibitors: omeprazole or pantoprazole and alendronate on bone remodeling in ovariectomized rats. The experiments were carried out on 3-month-old Wistar rats, divided into following groups (n = 8-10): NOVX - non-ovariectomized control rats; OVX - ovariectomized control rats; OVX + alendronate; OVX + omeprazole; OVX + omeprazole + alendronate; OVX + pantoprazole; OVX + pantoprazole + alendronate. The drugs were administered for 28 days: alendronate (3 mg/kg p.o.), omeprazole or pantoprazole (3 mg/kg i.p.). Bone remodeling was estimated based on histomorphometric evaluation of the tibia (endosteal and periosteal transverse growth and the osteoid width, transverse cross-section surface of the diaphysis and of the marrow cavity) and the femur (width of trabeculae in the distal epiphysis and metaphysis). Bone mass/100 g body mass and mass of bone mineral/100 mg bone mass in the tibia and femur were also determined. Pantoprazole stronger than omeprazole intensified bone remodeling disorders caused by estrogen deficiency in ovariectomized rats. Bone remodeling disorders were the result of intensification of bone resorption with concurrent inhibition of bone formation and mineralization. Pantoprazole, and to lesser extent omeprazole, weakened the preventive effect of alendronate on bone remodeling in ovariectomized rats.
authors.affiliation: Departament of Pharmacology, Medical University of Silesia, Katowice, Jagiellońska 4, 41-200 Sosnowiec, Poland. mariapytlik@gmail.com
authors.forename: Maria
authors.initials: M
authors.lastname: Pytlik
authors.forename: Urszula
authors.initials: U
authors.lastname: Cegieła
authors.forename: Barbara
authors.initials: B
authors.lastname: Nowińska
authors.forename: Joanna
authors.initials: J
authors.lastname: Folwarczna
authors.forename: Leszek
authors.initials: L
authors.lastname: Sliwiński
authors.forename: Ilona
authors.initials: I
authors.lastname: Kaczmarczyk-Sedlak
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Pytlik
authors.forename: Dorota
authors.initials: D
authors.lastname: Bolek
authors.forename: Hanna
authors.initials: H
authors.lastname: Korzeniowska
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000633:toxicity*; D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling; D004195:Disease Models, Animal; D005260:Female; D005269:Femur / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009853:Omeprazole / Q000633:toxicity*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010052:Ovariectomy; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D050071:Bone Density Conservation Agents; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole; D009853:Omeprazole; D019386:Alendronate